News
The 2nd Research Group Meeting in Okinawa: Transformative Research Area (A) – Emergence of Brain Functions from the Dynamic Connectome

Members of the Yonehara Lab participated in the 2nd Area Meeting, held at the Okinawa Institute of Science and Technology Graduate University (OIST) from December 8 to 10, 2025.

Read more
Lecture
The Associate Professors from Aarhus University, Dr. Naoki Yamawaki and Dr. Asami Tanimura, visited Yonehara Lab at NIG and had a biological symposium, “Cell-type-specific state-dependent activity of retrosplenial cortex (RSP): What does it represents?”.

The Associate Professor from Aarhus University, Dr. Naoki Yamawaki and Dr. Asami Tanimura, visited Yonehara Lab at NIG and had a biological symposium, “Cell-type-specific state-dependent activity of retrosplenial cortex (RSP): What does it represents?”.

Read more
Lecture
The professor from University of Helsinki, Dr. Petri Ala-Laurila, visited Yonehara Lab at NIG and had a biological symposium, “Linking image and non-image-forming vision to retinal circuitry at the sensitivity limit”.

The professor from University of Helsinki, Dr. Petri Ala-Laurila, visited Yonehara Lab at NIG and had a biological symposium, “Linking image and non-image-forming vision to retinal circuitry at the sensitivity limit”.

Read more
Lecture
The professor from VIB-KU Leuven, Dr. Karl Farrow, visited Yonehara Lab at NIG and had a biological symposium, “Circuits of the superior colliculus mediating innate behaviors”.

The professor from VIB-KU Leuven, Dr. Karl Farrow, visited Yonehara Lab at NIG and had a biological symposium, “Circuits of the superior colliculus mediating innate behaviors”.

Read more
Lecture
Dr. Akishi Onishi, Head of R&D at VCGT Inc., visited Yonehara Lab at NIG and had a biological symposium, “From Research to Reality: A Startup's Approach to Gene-Targeted Therapeutics for Inherited Retinal Diseases”.

Dr. Akishi Onishi, Head of R&D at VCGT Inc., visited Yonehara Lab at NIG and had a biological symposium, “From Research to Reality: A Startup's Approach to Gene-Targeted Therapeutics for Inherited Retinal Diseases”.

Read more